Real World Evidence

Real-World Evidence. Real Confidence. Real Results.

IQVIA Real World Solutions is the proven partner for real-world evidence that meets stakeholder needs with confidence, delivering real impact for clients, clinicians and patients.

A proven partner with a reputation you can trust

IQVIA Real World Solutions is a proven UK partner for the right real-world evidence to meet stakeholder needs with confidence, delivering real results.

IMPROVEMENTS IN PATIENT CARE

  • Filling gaps in knowledge which support access to new innovative treatments for patients. IQVIA has submitted 50 HTA submissions to NICE and SMCs since 2017.
  • Building greater understanding of medical treatments in real-world settings leading to improvements in patient care. IQVIA has been collecting over 62 million patient experience and audit outcomes in the UK per annum since 2009.

UNLOCKING THE VALUE OF INNOVATION

  • Building the evidence to show the real-world value of new and existing medicines to regulators and payers. IQVIA maximises efficiencies for access to these data through partnerships with high value data sources such as England’s national cancer registry database (CAS) and the world’s largest whole genome cohort for cancer and rare disease, Genomics England.
  • Establishing richer understanding of patient pathways, unlocking opportunities to reach new patient cohorts. IQVIA’s proprietary IMRD database comprises of 18 million patients' data across the UK covering different cohorts and diversity. IMRD has over 800 citations in peer reviewed journals.

IMPROVING POPULATION HEALTH IN THE UK

  • Informing clinical practice allows providers to identify greater efficiencies in the delivery of care that allows more patients to be treated at the right time with the right therapies. IQVIA is the trusted partner to identify these efficiencies, citing previous work with government-delivered COVID-19 survey in collaboration with ONS.
  • Supporting regulators, policy-makers, payers and providers by providing better understanding of the value for money, safety and efficacy of existing and new medicines within a broad population. IQVIA leverages over 90 experts in epidemiology, biostatistics and health economics to support in the delivery of a range of prospective and retrospective studies, healthcare evaluations and primary data collection.
  • Supporting development of new treatment pathways for previously underserved patient groups and empowering stakeholders with the evidence needed to drive meaningful policy change in healthcare to ultimately provide better outcomes.
  • Around 95% of NHS organisations use one or more of IQVIA’s services which allows IQVIA to build a deep and holistic understanding of how healthcare is delivered in the UK.

Leveraging Synthetic Data

IQVIA has taken a leading role in addressing data access challenges by partnering in the development and validation of the Simulacrum. This is a synthetic oncology dataset structured to model properties of the data collected within England’s national registry, the Cancer Analysis System (CAS), one of the largest and most detailed population-based cancer databases in the world.

Simulacrum is generated using sophisticated algorithms and privacy protecting processes to ensure that it contains no actual patient data. IQVIA has leveraged Simulacrum to accelerate real-world insight generation from the actual underlying CAS data. Through this innovative approach, IQVIA has already performed more than 50 clinically relevant and statistically precise studies that answer critical questions about cancer patients and their treatments without compromising patient confidentiality.

In 2022-3, IQVIA piloted an updated version of Simulacrum based on CAS Molecular Diagnostics data, a new dataset that provides information on somatic biomarker testing in routine clinical practice. The outputs of that pilot were published in PHUSE and in a poster presented at ISPOR:

Related Solution

Contact Us